MUCOSOLVAN 30/MG TAB 20/TAB

Indications

Approved Uses

Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport, such as acute and chronic bronchitis, bronchial asthma, and bronchiectasis.

Off-Label Uses

Sore throat pain relief (local anesthetic effect) is an established non-prescription use for ambroxol lozenges; other uses (e.g., neonatal RDS prevention, Gaucher/Parkinson’s) are formulation-/setting-specific and not applicable to this 30 mg oral tablet product.

Dosage & Administration

Dosing by Condition

Secretolytic therapy for productive cough/bronchopulmonary conditions (adults and ≥12 years): 30 mg three times daily initially, then 30 mg twice daily as maintenance; some references allow up to 60 mg twice daily in adults if needed.

Initial Dose

30 mg three times daily

Maintenance Dose

30mg two to three times daily.

Maximum Dose

Adults: maximum 90 mg/day for the 30 mg tablet (i.e., 30 mg three times daily), unless a clinician directs otherwise.

Dose Adjustment Notes

Use with caution in severe renal or hepatic impairment; consider reducing dose and/or extending dosing interval in severe impairment.

How to Take

Swallow the 30 mg tablet whole with water; may be taken with or without food; maintain adequate fluid intake.

Side Effects

Common Side Effects

Nausea, vomiting, diarrhea, abdominal pain/dyspepsia, and taste disturbance; oral/throat hypoesthesia (numbness) and dry mouth can occur.

Side Effect Frequency

Common (1-10%): nausea, dysgeusia (taste disturbance), oral/pharyngeal hypoesthesia (numbness). Uncommon (0.1-1%): vomiting, diarrhea, dyspepsia/indigestion, abdominal pain, dry mouth. Rare (0.01-0.1%): rash, urticaria. Not known: anaphylactic reactions and severe cutaneous adverse reactions (SJS/TEN).

Safety & Warnings

Contraindications

Contraindicated in patients with hypersensitivity to ambroxol hydrochloride or any excipients; avoid use in the first trimester of pregnancy.

Warnings & Precautions

Stop immediately and seek care if rash/blistering or mucosal lesions occur (SJS/TEN risk); use caution in peptic ulcer disease, impaired bronchial motility/large secretions, and in renal/hepatic impairment.

Drug Interactions

Drug Interactions

Avoid routine combination with antitussives (e.g., codeine/dextromethorphan) unless advised, due to risk of secretion retention; ambroxol may increase bronchopulmonary concentrations of some antibiotics (e.g., amoxicillin, cefuroxime, erythromycin), generally not harmful.

Interaction Severity

MODERATE: Concomitant antitussives (e.g., codeine/dextromethorphan) may impair mucus clearance and increase retention risk; MINOR/beneficial: certain antibiotics (e.g., amoxicillin, cefuroxime, erythromycin, doxycycline) may have increased bronchopulmonary penetration.

Special Populations

Kidney Impairment

Mild-moderate renal impairment: usually no adjustment; severe renal impairment (e.g., CrCl <30 mL/min): use with caution and consider extending dosing interval or reducing dose under medical supervision.

Storage & Patient Advice

Missed Dose

Take as soon as remembered; skip if near the time of the next dose; do not double the dose

Overdose

Expected overdose effects include GI symptoms (nausea, vomiting, diarrhea), hypersalivation, and possible hypotension/restlessness; management is supportive/symptomatic, consider decontamination if very recent/large ingestion, and seek medical attention.

Patient Counseling

Swallow with water and drink plenty of fluids; may take with or without food (take with food if GI upset). Avoid combining with cough suppressants unless advised. Do not exceed recommended dosing; seek care if symptoms persist/worsen after ~5-7 days or if severe rash/blistering occurs.

Monitoring Requirements

No routine monitoring required for most patients. Monitor renal and liver function in patients with pre-existing severe impairment.

Pharmacology

Mechanism of Action

Reduces mucus viscosity and enhances mucociliary clearance (mucolytic/secretolytic action) and increases surfactant production/release, reducing mucus adhesion and improving transport.

Onset of Action

Approximately 30 minutes (about 30-60 minutes).

Duration of Effect

Approximately 6-12 hours (immediate-release oral tablet).

Excretion

Primarily renal excretion, mostly as metabolites (majority of dose recovered in urine).

Product Information

Available Dosage Forms

Tablet, syrup, pastilles, sustained-release capsule, drops, inhalation solution, effervescent tablets.

Composition per Dose

Each tablet: 30 mg ambroxol hydrochloride

Generic Availability

Yes

OTC Alternatives

Acetylcysteine (NAC), carbocisteine, and guaifenesin-containing expectorants.

Symptom Target

Cough

Sedating

No

Reviewed by Al Mujtama Pharmacy Medical Review Team. Last reviewed 10-06-2026